Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer

• At least 1 measurable target lesion, as defined by RECIST

Exclusion Criteria:

• Thyroid lymphoma

• Previous treatment with anti-angiogenesis agents

• No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.